MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41467-025-55931-w

Медицинская библиотека · Nature communications · 2025

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

Zhang Bo, Fong Youyi, Dang Lauren, Fintzi Jonathan, Chen Shiyu, Wang Jing, Rouphael Nadine G, Branche Angela R, Diemert David J, Falsey Ann R, Graciaa Daniel S, Baden Lindsey R, Frey Sharon E, Whitaker Jennifer A, Little Susan J, Kamidani Satoshi, Walter Emmanuel B, Novak Richard M, Rupp Richard, Jackson Lisa A, Yu Chenchen, Magaret Craig A, Molitor Cindy, Borate Bhavesh, Busch Sydney, Benkeser David, Netzl Antonia, Smith Derek J, Babu Tara M, Kottkamp Angelica C, Luetkemeyer Anne F, Immergluck Lilly C, Presti Rachel M, Bäcker Martín, Winokur Patricia L, Mahgoub Siham M, Goepfert Paul A, Fusco Dahlene N, Atmar Robert L, Posavad Christine M, Mu Jinjian, Makowski Mat, Makhene Mamodikoe K, Nayak Seema U, Roberts Paul C, Gilbert Peter B, Follmann Dean, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 ("COVID-19") and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant Spike inserts assessed, both peak and exposure-proximal ("predicted-at-exposure") titers correlated with lower Omicron COVID-19 risk in individuals previously infected with SARS-CoV-2, albeit significantly less so in naïve individuals [e.g., exposure-proximal hazard ratio per 10-fold increase in BA.1 titer 0.74 (95% CI 0.59, 0.94) for naïve vs. 0.41 (95% CI 0.23, 0.64) for non-naïve; interaction p = 0.013]. Neutralizing antibody titer was a strong inverse correlate of Omicron COVID-19 in non-naïve individuals and a weaker correlate in naïve individuals, posing questions about how prior infection alters the neutralization correlate.

Для цитирования: Zhang Bo, Fong Youyi, Dang Lauren, Fintzi Jonathan, Chen Shiyu, Wang Jing, Rouphael Nadine G, Branche Angela R, Diemert David J, Falsey Ann R, Graciaa Daniel S, Baden Lindsey R, Frey Sharon E, Whitaker Jennifer A, Little Susan J, Kamidani Satoshi, Walter Emmanuel B, Novak Richard M, Rupp Richard, Jackson Lisa A, Yu Chenchen, Magaret Craig A, Molitor Cindy, Borate Bhavesh, Busch Sydney, Benkeser David, Netzl Antonia, Smith Derek J, Babu Tara M, Kottkamp Angelica C, Luetkemeyer Anne F, Immergluck Lilly C, Presti Rachel M, Bäcker Martín, Winokur Patricia L, Mahgoub Siham M, Goepfert Paul A, Fusco Dahlene N, Atmar Robert L, Posavad Christine M, Mu Jinjian, Makowski Mat, Makhene Mamodikoe K, Nayak Seema U, Roberts Paul C, Gilbert Peter B, Follmann Dean, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.. Nature communications. 2025. DOI: 10.1038/s41467-025-55931-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.